EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"University College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Receives DOD Award for Phase 2 Study on CX1739 in Spinal Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Ampakine

    Menu

    Ampakine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              RespireRx Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RespireRx Pharmaceuticals Receives DOD Award for Phase 2 Study on CX1739 in Spinal Injury

              Details:

              RespireRx intends to use the net proceeds to fund phase 2 clinical study of CX1739, its Lead AMPAkine, to improve bladder function in patients with spinal cord injury.

              Lead Product(s): Ampakine

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CX1739

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Department of Defense

              Deal Size: $1.8 million Upfront Cash: Undisclosed

              Deal Type: Funding May 29, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RespireRx Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

              Details:

              The collaboration aims to to study the possibility of using CX1739, RespireRx’s lead clinical AMPAkine, for the treatment of a major class of GRIA disorders.

              Lead Product(s): Ampakine

              Therapeutic Area: Rare Diseases and Disorders Product Name: CX1739

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: University College London

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY